Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFINITOR DISPERZ vs CERUBIDINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.
Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.
Advanced hormone receptor-positive, HER2-negative breast cancer (postmenopausal women, in combination with exemestane),Advanced neuroendocrine tumors of pancreatic origin (unresectable, locally advanced, or metastatic),Advanced neuroendocrine tumors of gastrointestinal or lung origin (unresectable, locally advanced, or metastatic),Renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery,Subependymal giant cell astrocytoma (SEGA) associated with TSC,Renal cell carcinoma (advanced, after failure of sunitinib or sorafenib),Prevention of organ rejection in renal and cardiac transplant recipients (off-label: liver transplant)
Acute myeloid leukemia,Acute lymphoblastic leukemia,Chronic myeloid leukemia in blast crisis,Kaposi's sarcoma (off-label)
10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.
45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.
Terminal half-life is approximately 30 hours (range 28-35 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Triphasic elimination: initial half-life 30 min (distribution), intermediate 3-5 hours (metabolism), terminal half-life 20-30 hours (slow elimination from tissues). Clinically relevant for scheduling and myelosuppression monitoring.
Everolimus is metabolized primarily by CYP3A4 and is a substrate of P-glycoprotein (P-gp). It is also a moderate inhibitor of CYP3A4 and P-gp.
Primarily hepatic metabolism via aldo-keto reductases to daunorubicinol (active metabolite), and further via CYP2D6 and carbonyl reductases.
Primarily fecal (80%) with 22% as unchanged drug; renal excretion <5%.
Primarily hepatic metabolism with biliary excretion (about 40% as unchanged drug and metabolites in bile). Renal excretion accounts for approximately 8-15% of the dose as unchanged drug and metabolites. Fecal elimination is less than 20%.
Approximately 74% bound to plasma proteins (mainly albumin).
Approximately 50-70% bound to plasma proteins, primarily albumin.
Mean apparent volume of distribution is 47 L (approximately 0.6 L/kg), indicating extensive tissue distribution.
Volume of distribution is high, ranging from 15-30 L/kg, indicating extensive tissue binding and distribution, particularly into erythrocytes and tissues.
Absolute bioavailability of the tablet formulation is approximately 16% after a high-fat meal; dispersible tablet bioavailability is comparable when taken with food.
Oral bioavailability is less than 5% due to extensive first-pass metabolism; therefore, not administered orally. IV administration results in 100% bioavailability.
For Cr Cl 30-50 m L/min: no adjustment required. For Cr Cl <30 m L/min: contraindicated or not recommended due to lack of data. No specific GFR-based dose reduction recommended.
Cr Cl 10–50 m L/min: reduce dose by 25%; Cr Cl <10 m L/min: reduce dose by 50%. Hemodialysis: administer after dialysis; dose reduction by 50%.
Child-Pugh A: reduce dose to 7.5 mg daily. Child-Pugh B: reduce dose to 5 mg daily. Child-Pugh C: contraindicated.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
For SEGA in TSC: weight-based dosing targeting AUC similar to adult 10 mg/day. Initial dose 2.5 mg/m² once daily, titrate to trough concentration 5-15 ng/m L. For TSC-associated renal angiomyolipoma: not established in pediatric patients.
25–45 mg/m² IV on days 1–3 every 21 days; neonates: <10 kg: 1 mg/kg IV daily for 3–5 days.
No specific dose adjustment required based on age alone; monitor renal function and dose adjust per renal/hepatic status. Elderly patients may have increased risk of adverse effects such as stomatitis, infections, and metabolic disturbances.
Initiate at lower end of dose range (30 mg/m²/day for 3 days) due to increased myelotoxicity; monitor renal function.
There is no FDA black box warning for Afinitor Disperz. However, serious infections, including opportunistic infections, may occur.
Severe myelosuppression; cumulative dose-related cardiotoxicity; extravasation with tissue necrosis; secondary leukemias.
Non-infectious pneumonitis (including interstitial lung disease) has been reported; monitor for symptoms and consider interruption or discontinuation.,Increased risk of infections, including opportunistic infections (e.g., Pneumocystis jirovecii, TB); monitor and treat promptly.,Increased serum creatinine and proteinuria may occur; monitor renal function.,Angioedema, including life-threatening cases, can occur, especially in patients taking ACE inhibitors.,Stomatitis and mouth ulcers are common; manage with topical treatments and dose modification.,Impaired wound healing; use with caution perioperatively.,Increased risk of bleeding, especially in patients with renal angiomyolipoma and TSC.,Fetal harm can occur; advise effective contraception during treatment.
Bone marrow suppression; cardiac toxicity (cumulative doses >550 mg/m²); hepatic and renal impairment; tumor lysis syndrome; immunosuppression.
Hypersensitivity to everolimus, sirolimus, or any component of the formulation,Severe hepatic impairment (Child-Pugh class C) (relative contraindication; use with caution in moderate impairment)
Severe myelosuppression; previous anthracycline therapy at maximum cumulative dose; severe hepatic impairment; severe cardiac disease; pregnancy.
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition. Avoid high-fat meals, as they reduce absorption; take on empty stomach or with light fat-free meal. St. John's wort reduces everolimus levels and should be avoided.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing toxicity. No other specific food restrictions reported.
Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fetal growth restriction, oligohydramnios, and spontaneous abortion.
Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal growth restriction, prematurity, and neonatal myelosuppression.
No data on excretion in human milk; M/P ratio unknown. Due to potential serious adverse reactions in nursing infants (e.g., immunosuppression), breastfeeding is contraindicated during treatment and for 2 weeks after last dose.
Contraindicated during breastfeeding. Daunorubicin is excreted into breast milk; M/P ratio unknown due to limited data. Potential for severe adverse effects in nursing infant including immunosuppression, cardiotoxicity, and carcinogenesis.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may reduce exposure; however, due to teratogenicity, use is not recommended unless benefit outweighs risk. Dose adjustments based on therapeutic drug monitoring are not validated.
No established dosing adjustments for pregnancy. Standard dosing based on body surface area, but use only if clearly needed due to teratogenicity. Increased volume of distribution may alter pharmacokinetics, but formal dose modifications not defined.
AFINITOR DISPERZ (everolimus) is an m TOR inhibitor; tablets for oral suspension are not interchangeable with regular tablets due to different pharmacokinetics. Monitor for non-infectious pneumonitis, rash, stomatitis, metabolic effects (hyperglycemia, hyperlipidemia), and renal impairment. Dose adjustments required for hepatic impairment and concurrent strong CYP3A4/P-gp inhibitors or inducers. Avoid live vaccines during treatment.
Cerubidine (daunorubicin) is an anthracycline antineoplastic antibiotic; premedicate with antiemetics; monitor for cardiotoxicity (cumulative dose limit 550 mg/m², or 450 mg/m² with prior chest radiation); administer via IV over 15-30 minutes to avoid extravasation (vesicant); observe for rapid lysis syndrome in high-tumor-burden patients; adjust dose for hepatic impairment (bilirubin >1.2 mg/d L).
Take exactly as prescribed; do not crush or chew tablets for oral suspension.,Mix dose with water only, do not mix with juice or other liquids.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any new or worsening shortness of breath, cough, or chest pain immediately.,Use effective non-hormonal contraception during and for 8 weeks after last dose.,Avoid live vaccines and close contact with recently vaccinated individuals.,Monitor for mouth sores; use alcohol-free mouthwash and soft toothbrush.,Do not take St. John's wort or strong CYP3A4/P-gp inhibitors/inducers without consulting doctor.
This drug may cause irreversible heart damage at high cumulative doses; report chest pain, shortness of breath, or swelling of ankles/feet.,You will need regular blood tests to monitor blood cell counts and heart function.,Notify your healthcare provider immediately if you experience pain, redness, or swelling at the injection site.,This medication can cause severe nausea and vomiting; antiemetic therapy will be given.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception; do not breastfeed while on this medication.,Your urine may appear reddish-orange for 1-2 days after treatment; this is harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFINITOR DISPERZ vs CERUBIDINE, answered by our medical review team.
AFINITOR DISPERZ is a mTOR Inhibitor Antineoplastic that works by Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.. CERUBIDINE is a Anthracycline antineoplastic that works by Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFINITOR DISPERZ and CERUBIDINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFINITOR DISPERZ is: 10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.. The standard adult dose of CERUBIDINE is: 45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFINITOR DISPERZ and CERUBIDINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFINITOR DISPERZ is classified as Category C. Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fet. CERUBIDINE is classified as Category C. Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.